It’s expanding its non-clinical expertise in derisking drug development with this acquisition
Together, they will join forces to provide their partners with non-invasive high-resolution imaging for their #preclinical projects. This collaboration enables optimal quantification of study endpoints and delivers greater confidence in biological results, empowering our clients to gain a deeper understanding of the mechanism of action of their therapies.
With 16 years of expertise in infectious diseases, Voxcan bring efficacy, biodistribution and tolerability studies to the ERBC Group. Their Biosafety Level 2 and 3 facilities offer a wide range of preclinical models to support research efforts.
This acquisition is another important step in ERBC Group’s strategy to build the leading independent non-clinical CRO in Europe, accelerating drug development from preclinical proof of concept to market.